Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2232
Title: Circulating Tumor DNA (ctDNA) as a marker of residual disease and recurrence risk in resected stage I IV epithelial ovarian cancer (EOC).
Epworth Authors: Ananda, Sumitra
Other Authors: Hong, Wei
Richardson, Gary
Lombard, Janine
Goss, Geraldine
Mileshkin, Linda
Steer, Christopher
O’Broin Lennon, Anne Marie
McNally, Orla
Douville, Christopher
Popoli, Maria
Ptak, Janine
Silliman, Natalie
Dobbyn, Lisa
Papadopoulos, Nicholas
Kinzler, Kenneth
Vogelstein, Bert
Tie, Jeanne
Gibbs, Peter
Keywords: Epithelial Ovarian Cancer
EOC
Relapse
Chemotherapy
Detectable ctDNA
Minimal Residual Disease
MRD
Recurrence
Recurrence Free Survival
RFS
Neoadjuvant Therapy
Post Adjuvant Chemotherapy
Issue Date: Oct-2023
Conference Name: Epworth HealthCare Research Month 2023
Conference Location: Epworth Research Institute, Victoria, Australia
Abstract: Patients with epithelial ovarian cancer (EOC) often relapse despite surgery and chemotherapy. Current prognosis estimates, based on FIGO staging molecular features lack precision. Standard of care for stage I III EOC is 6 cycles of adjuvant chemotherapy, which may include 3 cycles of neoadjuvant treatment. Many treated patients do not benefit from chemotherapy because they had no residual disease post operatively or because treatment did not eradicate disease that was present. Studies in multiple solid tumor types have demonstrated that after curative intent surgery detectable ctDNA a marker of minimal residual disease (MRD) predicts a very high risk of recurrence. Our primary aim was to explore the association between detectable ctDNA following debulking of primary EOC and recurrence free survival (RFS). Secondary aims included exploring the relationship between ctDNA and RFS at EOC diagnosis, following neoadjuvant therapy and post adjuvant chemotherapy. In a prospective cohort of patients with epithelial ovarian cancer analysed for ctDNA Neoadjuvant therapy cohort - ctDNA was detectable pre treatment in most patients. Most pre treatment ctDNA ve patients remained ctDNA ve despite chemotherapy. Post cancer cytoreduction surgery cohort - ctDNA was more likely to be detected in patients with stage III/IV disease, those with residual disease, and those without a BRCA mutation. ctDNA detection was associated with 2 year RFS. Post adjuvant chemotherapy cohort - ctDNA detection was associated with a trend to inferior 2 year RFS.
URI: http://hdl.handle.net/11434/2232
Type: Conference Poster
Affiliated Organisations: Walter and Eliza Hall Institute of Medical Research, Australia
Peter MacCallum Cancer Centre, Australia
Western Health, Australia
Department Of Medicine, University of Melbourne, Australia
Cabrini Health, Australia
Newcastle Private, Australia
John Hopkins University, School of Medicine, USA
Monash Medical Centre, Australia
Eastern Health, Australia
Mercy Hospital for Women, Heidelberg, Australia
Border Medical Oncology, Australia
Royal Women’s Hospital Parkville, Australia
Type of Clinical Study or Trial: Prospective Observational Study
Appears in Collections:Research Month

Files in This Item:
File Description SizeFormat  
ASCO Poster ctDNA Ovary Final 01082023 Epworth Research Week _SAnanda.pdf543.35 kBAdobe PDFThumbnail
View/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.